Safety concerns of COVID-19 Vaccines
Safety concerns of COVID-19 Vaccines
Safety concerns of COVID-19 Vaccines
Here we are listed out COVID-19 Vaccine’s safety concern.
-
BioNTech, Dated: 20 December 2020
The safety concerns of the COVID-19 mRNA vaccine in the initial RMP listed below
| Important Identified Risks | · Anaphylaxis |
| Important Potential Risks | · Vaccine-associated enhanced disease (VAED) including Vaccine-associated enhanced respiratory disease (VAERD) |
| Missing Information | · Use in pregnancy and while breast feeding
· Use in immunocompromised patients · Use in frail patients with co-morbidities (e.g., chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders) · Use in patients with autoimmune or inflammatory disorders · Interaction with other vaccines · Long term safety data |
- COVID-19 Vaccine AstraZeneca: ChAdOx1-S (recombinant). Dated: 04 November 2020
A summary of safety concerns for ChAdOx1-S (recombinant)is presented below
| Important Identified Risks | · None |
| Important Potential Risks | · Nervous system disorders, including immune-mediated neurological conditions
· Vaccine-associated enhanced disease (VAED), including vaccine associated enhanced respiratory disease (VAERD) · Anaphylaxis |
| Missing Information | · Use during pregnancy and while breastfeeding
· Use in immunocompromised patients · Use in frail patients with co-morbidities (eg, chronic obstructive pulmonary disease, diabetes, chronic neurological disease, cardiovascular disorders) · Use in patients with autoimmune or inflammatory disorders · Interactions with other vaccines · Long-term safety |
- COVID-19 Vaccine Janssen. Dated: 12 March 2021
Summary of Safety Concerns of (Ad26.COV2-S [recombinant]) are presented below
| Important Identified Risks | · Anaphylaxis |
| Important Potential Risks | · Vaccine-associated enhanced disease (VAED), including vaccine associated enhanced respiratory disease (VAERD)
· Venous thromboembolism |
| Missing Information | · Use in pregnancy and while breastfeeding
· Use in immunocompromised patients · Use in patients with autoimmune or inflammatory disorders · Use in frail patients with comorbidities (eg, chronic obstructive pulmonary disease [COPD], diabetes, chronic neurological disease cardiovascular disorders) · Interaction with other vaccines · Long-term safety |
- COVID-19 Vaccine Moderna. Dated: 06 January 2021
Summary of Safety Concerns of COVID-19 mRNA vaccine are presented below
| Important Identified Risks | · Anaphylaxis |
| Important Potential Risks | · Vaccine-associated enhanced disease (VAED), including vaccine associated enhanced respiratory disease (VAERD) |
| Missing Information | · Use in pregnancy and while breast-feeding
· Long term safety · Use in immunocompromised subjects · Interaction with other vaccines · Use in frail subjects with unstable health conditions and co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders) · Use in subjects with autoimmune or inflammatory disorders |
Source: European Medicines Agency (EMA)
Top articles related to Covid-19 Vaccines
- Pfizer-biontech-covid-19-vaccine-safety-data
- FDA-briefed-moderna-covid-19-vaccine-safety-data
- Oxford-University-Astrazeneca-covid-19-vaccine-safety-data
